Interview Ron van Schaik

Ron van Schaik Leadership and Change consultant Boertien Vergouwen Overduin LinkedIn

Ron van Schaik Cytochrome P450 3A4 (CYP3A4) is the most important drug metabolizing enzyme in the liver, responsible for the oxidative metabolism of ∼50% of clinically prescribed drugs.

20181103_19Wintersun Ron van Schaik Flickr

Prof. Dr. Ron van Schaik (PhD, FACB) is a registered European Specialist Laboratory Medicine and a Full Professor of Pharmacogenetics. He is working at the Dept. Clinical Chemistry at the Erasmus University Medical Center Rotterdam, and is Director of the International (IFCC) Expert-center for Pharmacogenetics.

Ronald van Schaik Werf&

Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. ML Becker, LE Visser, RHN van Schaik, A Hofman, AG Uitterlinden,. Diabetes 58 (3), 745-749. , 2009. 313.

Ron van Schaik Owner CGA Web Design LinkedIn

Awesome Books: your haven for affordable literary gems. Quality reads, unbeatable prices. Our extensive selection caters to all readers. Discover your next favourite book with us.

Interview Prof. Ron H. van Schaik YouTube

Prof. Dr. Ron van Schaik is hoogleraar Farmacogenetica, en leidt het Internationaal Expertise-laboratorium Farmacogenetica van de Afd. Klinische Chemie. Focus is implementatie van farmacogenetica. Wetenschappelijk onderzoek richt zich op de Oncologie (PGx en ctDNA analyses), Psychiatrie, Transplantatie en de Pijnbestrijding (opioiden.

Interview Ron van Schaik

31 okt. 2015 Activiteit Je gezondheid begint in je buik. Dat is me wel weer duidelijk geworden. Ik had vandaag een inspirerende eerste dag als directeur-bestuurder van de… Gemarkeerd als.

Ron SCHAIK Professor Erasmus MC, Rotterdam Erasmus MC Department of Clinical Chemistry (AKC)

Pharmacogenetics International Expertcenter - Prof. Dr. Ron H.N. van Schaik - Erasmus MC Research group/lab | Prof. Dr. Ron H.N. van Schaik Pharmacogenetics International Expertcenter Research is aimed at discovery and implementation of DNA analysis for personalizing drug therapy About our research group/lab Our research Key Publications

Nieuwe inzichten helpen patiënt in strijd tegen depressie Siemens Healthineers Nederland

New insights were provided by the esteemed keynote speakers, André G. Uitterlinden, Ron H.N. van Schaik, Roos van Westrhenen and all other speakers, Lone Fisker, Jordan Moore, Tiffany Morris, PhD.

5. SLOVENSKI KONGRES KLINIČNE KEMIJE IN LABORATORIJSKE MEDICINE

Prof. Dr. Ron van Schaik, PhD is a registered European specialist Laboratory medicine (2003) and a Full Professor of Pharmacogenetics (2013). He is working at the Dept. Clinical Chemistry at the Erasmus University Medical Center Rotterdam, The Netherlands.

Faculty of Pharmaceutical Sciences Ron van Schaik, PhD Michael Smith Laboratories

Interview Ron van Schaik 20 mei 2021 'Iedereen heeft recht op een DNA-paspoort' Ron van Schaik Professor farmacogenetica Nederland is vooralsnog het enige land ter wereld waar patiënten bij de apotheek medicatie op maat kunnen krijgen op basis van hun DNA-profiel.

Ron van Schaik • BioTech Pharma Summit

prof. dr. Ron van Schaik Full professor, Erasmus MC, Clinical Chemistry https://orcid.org/0000-0003-1864-2151 Overview Fingerprint Network Research output (402) Similar Profiles (1) Supervised Work (5) If you made any changes in Pure these will be visible here soon. Fingerprint Dive into the research topics where Ron van Schaik is active.

Interview Ron van Schaik

Dive into the research topics where Ron van Schaik is active. These topic labels come from the works of this person. Together they form a unique fingerprint. 1 Similar Profiles; Circulating Tumor DNA Medicine & Life Sciences 100%. Cytochrome P-450 CYP2D6 Medicine & Life Sciences 87%.

Forward Thinking An Interview with Ron Van Schaik PMF Features

Prof van Schaik has given over 200 invited lectures and participates on multiple national and international advisory committees on pharmacogenetics In 2001, he received the Ortho Clinical Diagnostics Award for Outstanding Research, in 2009 the AACC Outstanding Speaker Award, and in 2010 the AACC/Mol Pathology Award for Outstanding Scientific Research.

Ron H van Schaik, Professor, Erasmus University, Rotterdam, the Netherlands (3) YouTube

Simple Summary Although the introduction of programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICIs) has significantly improved the overall survival (OS) in patients with metastatic.

Interview Ronald van Schaik (Kaliber) op The Social Conference 2017 YouTube

Ron H.N. van Schaik Full Professor Pharmacogenetics / Head Dept Clinical Chemistry / Past-President European Society Pharmacogenomics & Personalised Therapy (ESPT) 10mo

Ron van Schaik Associate Professor Erasmus MC XING

Andrews, Louise ; Hesselink, Dennis; van Schaik, Ron et al. / A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.In: British Journal of Clinical Pharmacology. 2019 ; Vol. 85, No. 3. pp. 601-615.